ZYBERNO
Stock Report
Updated Sep 1, 2026

Genprex, Inc. (GNPX)

Healthcare • NASDAQ

$3.57

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Genprex, Inc. (GNPX) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-163.1%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.14x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-712.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Genprex, Inc. (GNPX) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:3.57
Market Cap:$1.69M

Valuation Multiples (2)

P/B Ratio:0.11x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$11.44M
B. Profitability Assessment

Return Metrics (5)

ROA:-129.0%
Reinvestment Rate:6.5%
Fundamental Growth Rate (g):-46.4%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$9.72
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-266.0%
Latest Earnings Filed:2022-03-30
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:6.77x
Quick Ratio:6.77x
Cash Ratio:6.47x

Leverage Analysis (3)

Debt To Equity Ttm:0.14x
Debt-to-Equity Ratio:0.14x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:13,500,971.00
Cash And Cash Equivalents:15,154,203.00
Long Term Debt:$0.00
Net Debt:-$13.13M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$15.84M

Bottom Line Performance (3)

-$16.50M
Income Before Tax:$0.00
Ebitda Ttm:-15,069,233.00

Operating Expenses (5)

Operating Expenses:15,842,711.00
R And D Expense:9,818,648.00
Sga Expense:6,024,063.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$17.14M
Current Assets:$15.84M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:2,341,864.00
Current Liabilities:2,341,864.00
Long Term Debt:$0.00
Short Term Debt:$2.03M

Equity & Capital (3)

Equity:$14.80M
Retained Earnings:-$179.94M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:293,579.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:68,354.00
C. Cash Flow Analysis

Operating Activities (2)

-$14.29M$0.00

Investment Activities (1)

Investing Cash Flow:$0.00

Financing Activities (3)

Financing Cash Flow:$13.36M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:13,356,857.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-27.01
-$0.42
Earnings Per Share Ttm:-$34.87

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$37.88

Book Value & Capital (2)

Book Value Per Share:$31.27
Cash Per Share:32.03

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:6.5%
Fundamental Growth Rate (g):-46.4%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-39.5%
C. Company Profile & Context

Corporate Information (6)

Symbol:GNPX
Company Name:Genprex, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:473.16K
Shares Outstanding Basic:473.16K
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 17:04:49 UTC
Data Timestamp:2026-08-21T22:46:16.356403
Scroll to Top